Not yet recruiting
Neovascular age-related macular degeneration
Not yet recruitingSafety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration
Registered drugNo placebo
Safety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration
Registered drugNo placebo
- Disease:Neovascular age-related macular degeneration
- Substances:AfliberceptOCUL101
Countries:
Czechia
Czechia- Participants:65+ years
- Substances:Aflibercept



